Viridian Therapeutics, Inc.\DE (VRDN) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$1.2 billion.

  • Viridian Therapeutics, Inc.\DE's Retained Earnings fell 3296.15% to -$1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 billion, marking a year-over-year decrease of 3296.15%. This contributed to the annual value of -$995.9 million for FY2024, which is 3718.78% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Retained Earnings stood at -$1.2 billion, which was down 3296.15% from -$1.2 billion recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Retained Earnings ranged from a high of -$297.3 million in Q1 2021 and a low of -$1.2 billion during Q3 2025
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Retained Earnings value was -$611.4 million (recorded in 2023), while the average stood at -$662.7 million.
  • Within the past 5 years, the most significant YoY rise in Viridian Therapeutics, Inc.\DE's Retained Earnings was 2847.5% (2021), while the steepest drop was 7507.77% (2021).
  • Viridian Therapeutics, Inc.\DE's Retained Earnings (Quarter) stood at -$358.3 million in 2021, then crashed by 36.25% to -$488.2 million in 2022, then plummeted by 48.7% to -$725.9 million in 2023, then plummeted by 37.19% to -$995.9 million in 2024, then fell by 22.32% to -$1.2 billion in 2025.
  • Its last three reported values are -$1.2 billion in Q3 2025, -$1.2 billion for Q2 2025, and -$1.1 billion during Q1 2025.